Biochemical Characterization of Highly Purified Leucine-Rich Repeat Kinases 1 and 2 Demonstrates Formation of Homodimers

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Civiero, Laura ^a   Vancraenenbroeck, Renée ^b   Belluzzi, Elisa ^a   Beilina, Alexandra ^c   Lobbestael, Evy ^b   Reyniers, Lauran ^b   Gao, Fangye ^b   Micetic, Ivan ^a   de Maeyer, Marc ^b   Bubacco, Luigi ^a   Baekelandt, Veerle ^b   Cookson, Mark R ^c   Greggio, Elisa ^a   Taymans, Jean Marc ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; GLYCINE; GUANIDINE; GUANOSINE TRIPHOSPHATASE; GUANOSINE TRIPHOSPHATE; HOMODIMER; LEUCINE RICH REPEAT KINASE 1; LEUCINE RICH REPEAT KINASE 2; MUTANT PROTEIN; PEPTIDE DERIVATIVE; PHOSPHOTRANSFERASE; RECOMBINANT ENZYME; RECOMBINANT LEUCINE RICH REPEAT KINASE 1; RECOMBINANT LEUCINE RICH REPEAT KINASE 2; SERINE; UNCLASSIFIED DRUG;

ALPHA HELIX; ARTICLE; AUTOPHOSPHORYLATION; BINDING AFFINITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BINDING; ENZYME CONFORMATION; ENZYME PHOSPHORYLATION; ENZYME PURIFICATION; ENZYME STABILITY; ENZYME SUBSTRATE; IMMUNOGOLD LABELING; IN VITRO STUDY; MOLECULAR MODEL; NONHUMAN; PARTICLE SIZE; POINT MUTATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN SECONDARY STRUCTURE; TRANSMISSION ELECTRON MICROSCOPY;

ADENOSINE TRIPHOSPHATE; CHROMATOGRAPHY; CIRCULAR DICHROISM; DIMERIZATION; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LENTIVIRUS; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, FLUORESCENCE; MUTATION; PHOSPHORYLATION; POINT MUTATION; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; PROTEINS;

EID: 84865583070     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043472     Document Type: Article

References (68)

1. Lewis PA, (2009) The function of ROCO proteins in health and disease. Biol Cell 101: 183-191.
2. Marin I, van Egmond WN, van Haastert PJ, (2008) The Roco protein family: a functional perspective. The FASEB Journal 22: 3103-3110.
3. Bosgraaf L, Van Haastert PJ, (2003) Roc, a Ras/GTPase domain in complex proteins. Biochim Biophys Acta 1643: 5-10.
4. Marin I, (2006) The Parkinson disease gene LRRK2: evolutionary and structural insights. MolBiolEvol 23: 2423-2433.
5. Marin I, (2008) Ancient origin of the Parkinson disease gene LRRK2. J Mol Evol 67: 41-50.
6. Dzamko N, Deak M, Hentati F, Reith AD, Prescott AR, et al. (2010) Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J 430: 405-413.
7. Nichols RJ, Dzamko N, Morrice NA, Campbell DG, Deak M, et al. (2010) 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J 430: 393-404.
8. Jorgensen ND, Peng Y, Ho CC, Rideout HJ, Petrey D, et al. (2009) The WD40 domain is required for LRRK2 neurotoxicity. PLoS One 4: e8463.
9. Piccoli G, Condliffe SB, Bauer M, Giesert F, Boldt K, et al. (2011) LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J Neurosci 31: 2225-2237.
10. Greggio E, Lewis PA, van der Brug MP, Ahmad R, Kaganovich A, et al. (2007) Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. J Neurochem 102: 93-102.
11. Korr D, Toschi L, Donner P, Pohlenz HD, Kreft B, et al. (2005) LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain. Cell Signal 18: 910-920.
12. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44: 595-600.
13. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44: 601-607.
14. Haugarvoll K, Toft M, Ross OA, White LR, Aasly JO, et al. (2007) Variants in the LRRK1 gene and susceptibility to Parkinson's disease in Norway. Neurosci Lett 416: 299-301.
15. Taylor JP, Hulihan MM, Kachergus JM, Melrose HL, Lincoln SJ, et al. (2007) Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson's disease. Neurogenetics 8: 95-102.
16. Daniels V, Vancraenenbroeck R, Law BM, Greggio E, Lobbestael E, et al. (2011) Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J Neurochem 116: 304-315.
17. Lewis PA, Greggio E, Beilina A, Jain S, Baker A, et al. (2007) The R1441C mutation of LRRK2 disrupts GTP hydrolysis. BiochemBiophysResCommun 357: 668-671.
18. Li X, Tan YC, Poulose S, Olanow CW, Huang XY, et al. (2007) Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem 103: 238-247.
19. Greggio E, Cookson MR, (2009) Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 1.
20. Greggio E, Taymans JM, Zhen EY, Ryder J, Vancraenenbroeck R, et al. (2009) The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem Biophys Res Commun 389: 449-454.
21. Ito G, Okai T, Fujino G, Takeda K, Ichijo H, et al. (2007) GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 46: 1380-1388.
22. West AB, Moore DJ, Choi C, Andrabi SA, Li X, et al. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. HumMolGenet 16: 223-232.
23. Taymans JM, Cookson M, (2010) Mechanisms of dominant parkinsonism; the toxic triangle of LRRK2, alpha-synuclein and tau. Bioessays 32: 227-235.
24. Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans JM, et al. (2008) The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. The Journal of Biological Chemistry 283: 16906-16914.
25. Sen S, Webber PJ, West AB, (2009) Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. J Biol Chem 284: 36346-36356.
26. Klein CL, Rovelli G, Springer W, Schall C, Gasser T, et al. (2009) Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment. J Neurochem 111: 703-715.
27. Berger Z, Smith KA, Lavoie MJ, (2010) Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. Biochemistry 49: 5511-5523.
28. Sen S, West AB, (2009) The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease. Antioxid Redox Signal 11: 2167-2187.
29. Carlessi R, Levin-Salomon V, Ciprut S, Bialik S, Berissi H, et al. (2011) GTP binding to the ROC domain of DAP-kinase regulates its function through intramolecular signalling. EMBO Rep 12: 917-923.
30. Gasper R, Meyer S, Gotthardt K, Sirajuddin M, Wittinghofer A, (2009) It takes two to tango: regulation of G proteins by dimerization. Nat Rev Mol Cell Biol 10: 423-429.
31. Deng J, Lewis PA, Greggio E, Sluch E, Beilina A, et al. (2008) Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci U S A 105: 1499-1504.
32. Gotthardt K, Weyand M, Kortholt A, Van Haastert PJ, Wittinghofer A, (2008) Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase. EMBO J 27: 2352.
33. Li X, Wang QJ, Pan N, Lee S, Zhao Y, et al. (2011) Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS One 6: e17153.
34. Gillardon F, (2009) Interaction of elongation factor 1-alpha with leucine-rich repeat kinase 2 impairs kinase activity and microtubule bundling in vitro. Neuroscience 163: 533-539.
35. Gandhi PN, Wang X, Zhu X, Chen SG, Wilson-Delfosse AL, (2008) The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J Neurosci Res 86: 1711-1720.
36. Wang L, Xie C, Greggio E, Parisiadou L, Shim H, et al. (2008) The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci 28: 3384-3391.
37. Rudenko IN, Kaganovich A, Hauser DN, Beylina A, Chia R, et al. (2012) The G2385R Variant of Leucine-Rich Repeat Kinase 2 Associated with Parkinson's Disease is a Partial Loss of Function Mutation. Biochem J.
38. Hanafusa H, Ishikawa K, Kedashiro S, Saigo T, Iemura S, et al. (2011) Leucine-rich repeat kinase LRRK1 regulates endosomal trafficking of the EGF receptor. Nat Commun 2: 158.
39. Titz B, Low T, Komisopoulou E, Chen SS, Rubbi L, et al. (2010) The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization. Oncogene 29: 5895-5910.
40. Brehme M, Hantschel O, Colinge J, Kaupe I, Planyavsky M, et al. (2009) Charting the molecular network of the drug target Bcr-Abl. Proc Natl Acad Sci U S A 106: 7414-7419.
41. Ito G, Iwatsubo T, (2012) Re-examination of the dimerization state of leucine-rich repeat kinase 2: predominance of the monomeric form. Biochem J 441: 987-994.
42. Baekelandt V, Claeys A, Eggermont K, Lauwers E, De Strooper B, et al. (2002) Characterization of lentiviral vector-mediated gene transfer in adult mouse brain. HumGene Ther 13: 841-853.
43. Geraerts M, Michiels M, Baekelandt V, Debyser Z, Gijsbers R, (2005) Upscaling of lentiviral vector production by tangential flow filtration. J Gene Med 7: 1299-1310.
44. Taymans JM, Vancraenenbroeck R, Ollikainen P, Beilina A, Lobbestael E, et al. (2011) LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding. PLoS One 6: e23207.
45. Ohi M, Li Y, Cheng Y, Walz T, (2004) Negative Staining and Image Classification- Powerful Tools in Modern Electron Microscopy. Biol Proced Online 6: 23-34.
46. Zhang J, Deng X, Choi HG, Alessi DR, Gray NS, (2012) Characterization of TAE684 as a potent LRRK2 kinase inhibitor. Bioorg Med Chem Lett 22: 1864-1869.
47. Ludtke SJ, Baldwin PR, Chiu W, (1999) EMAN: semiautomated software for high-resolution single-particle reconstructions. J Struct Biol 128: 82-97.
48. Frank J, Radermacher M, Penczek P, Zhu J, Li Y, et al. (1996) SPIDER and WEB: processing and visualization of images in 3D electron microscopy and related fields. J Struct Biol 116: 190-199.
49. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, et al. (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 405: 307-317.
50. Covy JP, Giasson BI, (2010) The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition. J Neurochem 115: 36-46.
51. Anand VS, Reichling LJ, Lipinski K, Stochaj W, Duan W, et al. (2009) Investigation of leucine-rich repeat kinase 2: enzymological properties and novel assays. FEBS J 276: 466-478.
52. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, et al. (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 405: 307-317.
53. Nichols RJ, Dzamko N, Hutti JE, Cantley LC, Deak M, et al. (2009) Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J 424: 47-60.
54. Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans J-M, et al. (2008) The Parkinson Disease-associated Leucine-rich Repeat Kinase 2 (LRRK2) Is a Dimer That Undergoes Intramolecular Autophosphorylation. J Biol Chem 283: 16906-16914.
55. Deng X, Dzamko N, Prescott A, Davies P, Liu Q, et al. (2011) Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol 7: 203-205.
56. Vancraenenbroeck R, Lobbestael E, Maeyer MD, Baekelandt V, Taymans JM, (2011) Kinases as targets for Parkinson's disease: from genetics to therapy. CNS Neurol Disord Drug Targets 10: 724-740.
57. Huse M, Kuriyan J, (2002) The conformational plasticity of protein kinases. Cell 109: 275-282.
58. Nolen B, Taylor S, Ghosh G, (2004) Regulation of protein kinases; controlling activity through activation segment conformation. Mol Cell 15: 661-675.
59. Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans JM, et al. (2008) The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem 283: 16906-16914.
60. Lu B, Zhai Y, Wu C, Pang X, Xu Z, et al. (2010) Expression, purification and preliminary biochemical studies of the N-terminal domain of leucine-rich repeat kinase 2. Biochim Biophys Acta 1804: 1780-1784.
61. Luzon-Toro B, Rubio de la Torre E, Delgado A, Perez-Tur J, Hilfiker S, (2007) Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Hum Mol Genet 16: 2031-2039.
62. Liu M, Kang S, Ray S, Jackson J, Zaitsev AD, et al. (2011) Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant. Biochemistry 50: 9399-9408.
63. Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, et al. (2006) The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. HumMolGenet 15: 223-232.
64. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. NeurobiolDis 23: 329-341.
65. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, et al. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102: 16842-16847.
66. Greggio E, Lewis PA, van der Brug MP, Ahmad R, Kaganovich A, et al. (2007) Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. J Neurochem 102: 93-102.
67. Morrison DK, (2009) The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol 19: 16-23.
68. Piccoli G, Condliffe SB, Bauer M, Giesert F, Boldt K, et al. (2011) LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. Journal of Neuroscience 31: 2225-2237.